Cilostazol This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog.Subscribe to this data using Feedly.
This page shows you the latest news and research items in this category.
Effects of Chronic Treatment With Cilostazol, a Phosphodiesterase 3 Inhibitor, on Female Rat Bladder in a Partial Bladder Outlet Obstruction Model
Conclusion: PDE3i has a small but significant protective effect on the contractile dysfunction induced by a 4-week BOO in rats, although the increase in bladder mass was not altered. PDE3i could be a useful protection against contractile dysfunction of the obstructed bladder. (Source: Urology)
Source: Urology - February 27, 2014 Category: Urology & Nephrology Authors: Seiji Matsumoto, Masaki Watanabe, Kazumi Hashizume, Naoki Wada, Jun-ichi Hori, Masafumi Kita, Tatsuya Iwata, Hidehiro Kakizaki Tags: Basic and Translational Science Source Type: research
Semi‐Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Anti‐Platelet Agents
This article is protected by copyright. All rights reserved. (Source: Basic and Clinical Pharmacology and Toxicology)
Source: Basic and Clinical Pharmacology and Toxicology - February 24, 2014 Category: Drugs & Pharmacology Authors: Hwi‐yeol Yun, Wonku Kang, Byung‐yo Lee, Sunkyung Park, Young‐Ran Yoon, Kwang‐il Kwon Tags: Original Article Source Type: research
Homocysteine as a Predictor of Early Neurological Deterioration in Acute Ischemic Stroke [Brief Reports]
Conclusions— Patients with acute stroke with elevated serum homocysteine levels are at an increased risk for END. (Source: Stroke)
Source: Stroke - February 24, 2014 Category: Neurology Authors: Kwon, H.-M., Lee, Y.-S., Bae, H.-J., Kang, D.-W. Tags: Risk Factors, Epidemiology Brief Reports Source Type: research
A Systematic Approach to Design and Prepare Solid Dispersions of Poorly Water-Soluble Drug.
The objective of the present study was to define a systematic approach to design and prepare solid dispersions of poorly water-soluble drug. The systematic approach can be defined in four phases. In the first phase, glass forming ability is assessed, and in the second phase, probable excipients are screened. The screened excipients are evaluated (third phase) for glass transition temperatures (T g) and miscibility studies according to Florey-Huggins interaction parameter. The predicted excipients are used to prepare the solid dispersion and evaluated for T g and any interactions using Fourier transfer infrared studies (fou...
Source: AAPS PharmSciTech - February 22, 2014 Category: Drugs & Pharmacology Authors: Verma S, Rudraraju VS Tags: AAPS PharmSciTech Source Type: research
Cellular Mechanism Underlying Hypothermia-Induced Ventricular Tachycardia/Ventricular Fibrillation in the Setting of Early Repolarization and the Protective Effect of Quinidine, Cilostazol, and Milrinone [Original Articles]
Conclusions— Hypothermia leads to VT/VF in the setting of ER by exaggerating repolarization abnormalities, leading to development of phase 2 reentry. Quinidine, cilostazol, and milrinone suppress the hypothermia-induced VT/VF by reversing the repolarization abnormalities. (Source: Circulation: Arrhythmia and Electrophysiology)
Source: Circulation: Arrhythmia and Electrophysiology - February 18, 2014 Category: Cardiology Authors: Gurabi, Z., Koncz, I., Patocskai, B., Nesterenko, V. V., Antzelevitch, C. Tags: Arrythmias-basic studies Original Articles Source Type: research
Effects of Cilostazol on Oxidative Stress, Systemic Cytokine Release, and Spinal Cord Injury in a Rat Model of Transient Aortic Occlusion
Conclusion: The present experimental study indicated that cilostazol pretreatment used in this study before aortic occlusion decreased lipid peroxidation, which may be related to the reduction of reactive oxygen species. Cilostazol did not significantly suppress systemic cytokine release and prevent spinal cord inflammation and injury; however, it did show some benefit. Additional investigations might be needed to determine the critical dose of cilostazol for clarifying the protective role of this drug in spinal cord ischemia/reperfusion injury. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - February 1, 2014 Category: Surgery Authors: Tunay Kurtoglu, Harun Basoglu, Erdem Ali Ozkisacik, Nesibe Kahraman Cetin, Canten Tataroglu, Cigdem Yenisey, Berent Discigil Tags: Basic Science Source Type: research
Cilostazol: same evidence, different conclusions.
PMID: 24493552 [PubMed - in process] (Source: Chest)
Source: Chest - February 1, 2014 Category: Respiratory Medicine Authors: Bellmunt S, Alonso-Coello P Tags: Chest Source Type: research
Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease
We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management. A Markov decision model was developed to assess the lifetime costs and benefits of each vasoactive drug compared to no vasoactive drug and with each other. Regression analysis was undertaken to model the relationship between maximum walking distance and utility. Resource use data were sourced from the literature and sensitivity analyses were undertaken. Naftidrofuryl oxalate is more ef...
Source: Angiology - January 30, 2014 Category: Cardiology Authors: Meng, Y., Squires, H., Stevens, J. W., Simpson, E., Harnan, S., Thomas, S., Michaels, J., Stansby, G., O'Donnell, M. E. Tags: Peripheral Arterial Disease Source Type: research
Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1.
Abstract Hepatic steatosis is common in obese individuals with hyperinsulinemia and is an important hepatic manifestation of metabolic syndrome. Sterol regulatory binding protein-1c (SREBP-1c) is a master regulator of lipogenic gene expression in the liver. Hyperinsulinemia induces transcription of SREBP-1c via activation of liver X receptor (LXR) and specificity protein 1 (Sp1). Cilostazol is an antiplatelet agent that prevents atherosclerosis and decreases serum triglyceride levels. However, little is known about the effects of cilostazol on hepatic lipogenesis. Here, we examined the role of cilostazol in the reg...
Source: exp Mol Med - January 28, 2014 Category: Molecular Biology Authors: Jung YA, Kim HK, Bae KH, Seo HY, Kim HS, Jang BK, Jung GS, Lee IK, Kim MK, Park KG Tags: Exp Mol Med Source Type: research
Long term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive down-regulation of phosphodiesterase 3B.
Abstract The lipid lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of non-esterified fatty acids (NEFA) to the circulation. However, long term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the underlying mechanisms are poorly understood. The current study addressed the effects of long term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated with n...
Source: Am J Physiol Endocri... - January 28, 2014 Category: Endocrinology Authors: Heemskerk MM, van den Berg SA, Pronk AC, Van Klinken J, Boon MR, Havekes LM, Rensen PC, Willems van Dijk K, van Harmelen V Tags: Am J Physiol Endocrinol Metab Source Type: research
Neurovascular protection of cilostazol in stroke‐prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation
This study sought to evaluate the effects of commonly used antiplatelet drugs on spontaneous cerebral infarction in relation to neurovascular protection associated with angiogenesis and pericyte proliferation. Stroke‐prone spontaneously hypertensive rats (SHR‐SP) were treated with vehicle, aspirin, clopidogrel, or cilostazol from 8 to 10 weeks of age. The interaction of neurovascular components among endothelial cells, pericytes, and astrocytic endfeet were immunohistochemically examined in brain sections. Angiogenesis associated with vascular endothelial growth factor receptor 2 (VEGFR2) and pericyte proliferation wer...
Source: Journal of Neuroscience Research - December 21, 2013 Category: Neuroscience Authors: Yoshio Omote, Kentaro Deguchi, Syoichiro Kono, Ning Liu, Wentao Liu, Tomoko Kurata, Toru Yamashita, Yoshio Ikeda, Koji Abe Tags: Research Article Source Type: research
In vitro effects of cilostazol, a phosphodiesterase 3A inhibitor, on mouse oocyte maturation and morphology.
This study was designed to investigate the potential inhibitory effects of CLZ on oocyte maturation and morphology in vitro Antral oocytes were recovered from hyperstimulated mice and allocated to 10 different CLZ concentrations (0.00-67.66μM). Oocytes were then assessed after 24 and 48h of incubation for maturation and morphology. Some of the evaluated CLZ concentrations (1.06-4.23μM) were made similar to those observed in human clinical trials. CLZ arrested oocyte maturation at the germinal vesicle (GV) stage at concentrations as low as 1.06μM (P<0.0001). A selective degenerative impact of CLZ targeting arrested oo...
Source: Clinical and Experimental Pharmacology and Physiology - December 17, 2013 Category: Drugs & Pharmacology Authors: Taiyeb AM, Dees WL, Ridha-Albarzanchi MT, Sayes CM, Kraemer DC Tags: Clin Exp Pharmacol Physiol Source Type: research
Differential Effect of Phosphodiesterase-3 Inhibitors on Sympathetic Hyperinnervation in Healed Rat Infarcts.
Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation. PMID: 24304537 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - December 4, 2013 Category: Cardiology Authors: Lee TM, Lin SZ, Chang NC Tags: Circ J Source Type: research
Cilostazol inhibits leukocyte-endothelial cell interactions in murine microvessels after transient bilateral common carotid artery occlusion.
Abstract Leukocyte behavior in the cerebral microvasculature following vessel occlusion has not been fully elucidated. The purpose of this study was to investigate the effects of cilostazol on leukocyte behavior (rolling and adhesion) in murine cerebral microvessels following transient bilateral carotid artery occlusion using intravital fluorescence microscopy. Four groups of mice were assigned: a sham group (n=16); an ischemia (induced by 15-min occlusion of bilateral common carotid arteries) and reperfusion (I/R) group (n=13); I/R+cilostazol (I/R+CZ3mg/kg) group (I/R after oral administration of cilostazol at 3mg...
Source: Brain Research - December 2, 2013 Category: Neurology Authors: Fukuoka T, Hayashi T, Hirayama M, Maruyama H, Tanahashi N Tags: Brain Res Source Type: research
Preparation and Characterization of Microemulsion of Cilostazol for Enhancement of Oral Bioavailability.
In this study, Capmul MCM C8 (glycerol monocaprylate) based MEs containing Tween 20(polysorbate 20) and/or Labrafil M 1944(poly oxyglycerides) as surfactant(S) and Transcutol P(diethyl glycol monoethyl ether) as cosurfactant(CoS) were studied as potential delivery systems of cilostazol. A number of such systems were prepared containing different S:CoS ratios(1:1, 2:1 and 3:1) based on phase diagrams. Loading of cilostazol was selected as per solubilization capacity and were characterized for pH, viscosity, conductivity, particle size, zeta potential and % transmittance. The MEs systems were further investigated for chemica...
Source: Current Drug Delivery - November 26, 2013 Category: Drugs & Pharmacology Authors: Patel SG, Rajput SJ, Groshev A, Sutariya VB Tags: Curr Drug Deliv Source Type: research
Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
CONCLUSION: Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF). PMID: 24280344 [PubMed - as supplied by publisher] (Source: Perfusion)
Source: Perfusion - November 26, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Alizade E, Sahin M, Simsek Z, Açar G, Bulut M, Güler A, Avci A, Kalkan M, Pala S, Akçakoyun M, Esen A Tags: Perfusion Source Type: research
Attenuation of β‐amyloid‐induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol
In conclusion, increased cAMP‐dependent protein kinase‐linked CK2/SIRT1 expression by cilostazol can be a therapeutic strategy to suppress the tau‐related neurodegeneration in the AD brain. © 2013 Wiley Periodicals, Inc. (Source: Journal of Neuroscience Research)
Source: Journal of Neuroscience Research - November 19, 2013 Category: Neuroscience Authors: Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim Tags: Research Article Source Type: research
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis
Conclusions: Adjunctive cilostazol (triple antiplatelet therapy) in clopidogrel-resistant patients reduces the rate of clopidogrel resistance and suppresses new ischemic lesions without hemorrhagic complications, as compared with standard DAT. Antiplatelet management based on the evaluation of antiplatelet resistance would be required for prevention of perioperative thromboembolic complications in CAS. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - November 18, 2013 Category: Surgery Authors: Ichiro Nakagawa, Takeshi Wada, Hun Soo Park, Fumihiko Nishimura, Syuichi Yamada, Hiroyuki Nakagawa, Kimihiko Kichikawa, Hiroyuki Nakase Tags: Clinical research studies Source Type: research
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Abstract The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. PMID: 24227374 [PubMed - in process] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - November 17, 2013 Category: Surgery Authors: Roset PN Tags: Br J Surg Source Type: research
Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Source: The British Journal of Surgery - November 17, 2013 Category: Surgery Authors: Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638). Tags: Br J Surg Source Type: research
Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638)
(Source: British Journal of Surgery)
Source: British Journal of Surgery - November 14, 2013 Category: Surgery Authors: J.W. Stevens, E. Simpson, S. Harnan, H. Squires, Y. Meng, S. Thomas, J. Michaels, G. Stansby Tags: Your Views Source Type: research
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638)
The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. (Source: British Journal of Surgery)
Source: British Journal of Surgery - November 14, 2013 Category: Surgery Authors: P. N. Roset Tags: Your Views Source Type: research
Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis
Abstract: Previous studies with small sample size have shown that cilostazol can reduce the risk of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH). The purpose of this study was to determine whether cilostazol is effective in patients with aneurysmal SAH. Studies investigating the effect of cilostazol in patients with aneurysmal SAH were identified using Embase.com without language or publication-type restrictions. We used the random-effect model to combine data. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated. Two randomized controlled trials and two quasi-randomized...
Source: Journal of the Neurological Sciences - November 11, 2013 Category: Neurology Authors: Peng-Peng Niu, Ge Yang, Ying-Qi Xing, Zhen-Ni Guo, Yi Yang Tags: Original Articles Source Type: research
Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention
BackgroundWe investigated the pharmacodynamic effect of cilostazol addition (100 mg twice, Triple) or clopidogrel doubling (150 mg daily, Double) on standard dual antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients with clopidogrel resistance undergoing a percutaneous coronary intervention. Methods and resultsThis was a prospective, randomized, cross-over platelet function study. Percent inhibition less than 20% was used as the cutoff value of clopidogrel resistance. After percutaneous coronary intervention, a total of 50 T2DM patients with clopidogrel resistance were assigned to receive cilostazol 100 mg twic...
Source: Coronary Artery Disease - November 8, 2013 Category: Cardiology Tags: Original Research Source Type: research
Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions: A Meta-Analysis
Conclusion: Addition of cilostazol to conventional dual antiplatelet therapy significantly lowers platelet reactivity and may explain a decrease in thromboembolic events following coronary intervention; however, additional studies evaluating clinical outcomes will be helpful to determine the benefit of triple antiplatelet therapy. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - November 8, 2013 Category: Cardiology Authors: Panchal, H. B., Shah, T., Patel, P., Albalbissi, K., Molnar, J., Coffey, B., Khosla, S., Ramu, V. Tags: Clinical Studies Source Type: research
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Conclusions These results indicate that cilostazol is neuroprotective in the chronically compressed cervical cord and is potentially useful in the treatment of cervical spondylotic myelopathy. PMID: 24206033 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - November 8, 2013 Category: Neurosurgery Authors: Yamamoto S, Kurokawa R, Kim P Tags: J Neurosurg Spine Source Type: research
Treatment Options for Patients With Poor Clopidogrel Response
A significant percentage of patients demonstrate a poor antiplatelet response to clopidogrel. With the emergence of testing for genetic variations in drug-metabolizing enzyme function and testing for platelet function, it is becoming more common to identify patients as poor responders to clopidogrel. This leaves the clinician in a difficult situation when confronted with a patient deemed to be a poor clopidogrel responder as there is no clear therapeutic strategy for treating these patients. In this situation, a number of alternatives to conventional dosing of clopidogrel have been investigated, including increasing the do...
Source: Cardiology in Review - November 1, 2013 Category: Cardiology Tags: Feature Curbside Consult Source Type: research
Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study
Cilostazol reduces angiographic restenosis for femoropopliteal lesions after percutaneous transluminal angioplasty with provisional nitinol stenting. Use of nitinol stents has improved long-term outcomes of endovascular therapy for femoropopliteal lesions compared with balloon angioplasty alone (Schillinger M et al, N Engl J Med 2006;354:1879-88; and Laird JR et al, Circ Cardiovasc Interv 2010;3:267-76). However, even with the use of stents, there remains a 20% to 50% incidence of restenosis at 1 year. The present study was designed to determine, using angiographic follow-up, whether treatment with cilostazol reduces rest...
Source: Journal of Vascular Surgery - October 28, 2013 Category: Surgery Authors: O. Iida, H. Yokoi, Y. Soga, STOP-IC investigators Tags: Abstracts Source Type: research
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease
Conclusions: In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up. (Source: American Heart Journal)
Source: American Heart Journal - October 24, 2013 Category: Cardiology Authors: Young Jin Youn, Jun-Won Lee, Sung Gyun Ahn, Seung-Hwan Lee, Hyunmin Choi, Cheol Woong Yu, Young Joon Hong, Hyuck Moon Kwon, Myeong-Ki Hong, Yangsoo Jang, Junghan Yoon Tags: Interventional Cardiology Source Type: research
The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression
Conclusion: Taken together, our results demonstrated that cilostazol enhances LRP1 expression in liver by activating PPARγ through the PPRE in the LRP1 promoter. Increased hepatic LRP1 may be essential for the reduction of circulating triglycerides brought about by cilostazol. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - October 21, 2013 Category: Biomedical Science Authors: Hyung Jun Kim, Jae Hoon Moon, Hyun Min Kim, Mi Ra Yun, Byung Hun Jeon, ByungWan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha Tags: Basic Science Source Type: research
Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits
Conclusion: We found that the PB group and the PB+CZ group exhibited a reduction in the lesion areas (70% in the PB+CZ group, 56% in the PB group) compared with the vehicle group. However, although PB alone and PB+CZ led to a reduction in the lesion size, the histological analysis revealed that only PB+CZ significantly decreased the macrophage accumulation and smooth muscle cell proliferation in the lesions compared with the vehicle group. The plasma levels of total cholesterol in the PB+CZ group were decreased compared with the vehicle group, Moreover, PB+CZ exerted obvious anti-oxidant and anti-inflammatory effects. Inte...
Source: Thrombosis Research - October 2, 2013 Category: Hematology Authors: Yulong Chen, Sihai Zhao, Bingqiao Huang, Yanli Wang, Yafeng Li, Ahmed Bilal Waqar, Ruihan Liu, Liang Bai, Jianglin Fan, Enqi Liu Tags: Platelets and Cell Biology Source Type: research
Cilostazol Is Associated with Improved Outcomes after Peripheral Endovascular Interventions: A Meta-Analysis
While cilostazol is commonly used as an adjunct following peripheral vascular interventions (PVI), its efficacy remains uncertain. We assessed the effect of cilostazol on outcomes following PVI using meta-analytic techniques. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - October 1, 2013 Category: Surgery Authors: Courtney J. Warner, Spencer W. Greaves, Robin J. Larson, Randall R. De Martino, Richard J. Powell, Daniel B. Walsh, Philip P. Goodney Tags: Abstracts from the 2013 Eastern Vascular Society Annual Meeting Source Type: research
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease
ConclusionTAPT after drug-eluting stent implantation in patients with uLMCAD did not improve the long-term clinical outcome when compared with conventional DAPT, although it was a safe strategy. (Source: Coronary Artery Disease)
Source: Coronary Artery Disease - September 30, 2013 Category: Cardiology Tags: Original Research Source Type: research
Cilostazol Ameliorates Warfarin-Induced Hemorrhagic Transformation After Cerebral Ischemia in Mice [Basic Sciences]
Conclusions— Cilostazol reduced the warfarin-related risk of HT after ischemia by protecting the vascular endothelial cells. This result suggested that cilostazol administration in patients with acute ischemic stroke might reduce HT. (Source: Stroke)
Source: Stroke - September 23, 2013 Category: Neurology Authors: Kitashoji, A., Egashira, Y., Mishiro, K., Suzuki, Y., Ito, H., Tsuruma, K., Shimazawa, M., Hara, H. Tags: Cerebrovascular disease/stroke, Animal models of human disease, Other anticoagulants, Intracerebral Hemorrhage, Anticoagulants Basic Sciences Source Type: research
Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials)
In conclusion, the triple group had a significantly reduced ISR in patients with >40-mm stent length after DES implantation compared with the dual group. Therefore, this suggestion for use of triple antiplatelet therapy could be easily applied after DES implantation in routine clinical practice. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - September 23, 2013 Category: Cardiology Authors: Seung-Whan Lee, Jong-Young Lee, Jung-Min Ahn, Duk-Woo Park, Seungbong Han, Yong Kyu Park, Woo Seok Lee, Jeong Yoon Jang, Chang Hee Kwon, Gyung-Min Park, Young-Rak Cho, Won-Jang Kim, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee, Jae-Joong Kim, Seong-Wook Pa Tags: Coronary Artery Disease Source Type: research
Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news
J wave syndromes: Molecular and cellular mechanisms
Abstract: An early repolarization (ER) pattern in the ECG, consisting of J point elevation, distinct J wave with or without ST segment elevation or slurring of the terminal part of the QRS, was long considered a benign electrocardiographic manifestation. Experimental studies a dozen years ago suggested that an ER is not always benign, but may be associated with malignant arrhythmias. Validation of this hypothesis derives from recent case–control and population-based studies showing that an ER pattern in inferior or infero-lateral leads is associated with increased risk for life-threatening arrhythmias, termed early repol...
Source: Journal of Electrocardiology - September 9, 2013 Category: Cardiology Authors: Charles Antzelevitch Tags: Session II: J wave syndromes and sudden cardiac death. From cell to bedside - Chair: Charles Antzelevitch, Co-Chair: Peter Macfarlane Source Type: research
Impaired platelet P2Y12 inhibition by thienopyridines * in chronic kidney disease: mechanisms, clinical relevance * and pharmacological options
Patients with chronic kidney disease (CKD) represent an increasing proportion of the population undergoing percutaneous coronary intervention (PCI) and up to 40% of the patients treated for acute coronary syndrome (ACS). Several studies and registries in the setting of ACS and elective PCI have reported a negative association between CKD and mortality, stent thrombosis, post-procedural ischaemic events and bleeding events. Pharmacological inhibition of the adenosine diphosphate receptor by thienopyridines or ticagrelor and disruption of the cyclooxygenase pathway by aspirin constitute the current standards of care to preve...
Source: Nephrology Dialysis Transplantation - September 6, 2013 Category: Urology & Nephrology Authors: Morel, O., Muller, C., Jesel, L., Moulin, B., Hannedouche, T. Tags: REVIEW - CLINICAL SCIENCE AND OUTCOME RESEARCH IN NEPHROLOGY Source Type: research
Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction.
CONCLUSION: Our study demonstrates that prasugrel could produce a significantly greater peri-procedural as well as in-hospital IPA compared with TAP in patients with STEMI undergoing primary PCI. PMID: 24012432 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - September 5, 2013 Category: Cardiology Authors: Park KH, Jeong MH, Lee KH, Sim DS, Yoon HJ, Yoon NS, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC Tags: J Cardiol Source Type: research
The effect of ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects
ConclusionsCo‐administration of GBE showed no statistically significant effects on the pharmacokinetics of cilostazol in healthy subjects. The long‐term large cohort clinical study seems to be remained to evaluate the possible pharmacodynamic interaction between cilostazol and GBE, since there was remarkable, but no statistically significant, increase of platelet aggregation inhibition. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - September 3, 2013 Category: Drugs & Pharmacology Authors: Ho‐Sook Kim, Ga‐young Kim, Chang‐Woo Yeo, Minkyung Oh, Jong‐lyul Ghim, Ji‐Hong Shon, Eun‐Young Kim, Dong‐Hyun Kim, Jae‐Gook Shin Tags: Clinical trials Source Type: research
Diagnosis and treatment of peripheral arterial disease.
Abstract Peripheral arterial disease (PAD) is atherosclerosis leading to narrowing of the major arteries distal to the aortic arch. The most common presenting symptom is claudication; however, only 10% of patients have classic claudication. Approximately 8 to 12 million Americans have PAD, including 15% to 20% of adults older than 70 years. The ankle-brachial index (ABI) can be used to screen for and diagnose PAD in the primary care setting. An ABI of less than 0.9 is associated with a two- to fourfold increase in relative risk for cardiovascular events and all-cause mortality. To improve cardiovascular risk strati...
Source: American Family Physician - September 1, 2013 Category: Primary Care Authors: Hennion DR, Siano KA Tags: Am Fam Physician Source Type: research
Efficacy and Safety of Triple Antiplatelet Therapy in Obese Patients Undergoing Stent Implantation
We evaluated the impact of triple antiplatelet therapy on platelet reactivity, reducing cardiovascular events and the safety in obese patients undergoing coronary stenting. Obese patients (n = 428) undergoing coronary stenting were randomly assigned to 2 groups: standard dual group (clopidogrel plus aspirin, n = 215) and triple group (n = 213); adjunctive cilostazol was added to the dual group treatment. Platelet reactivity was assessed at baseline and at 1-year follow-up by conventional aggregometry. Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularizati...
Source: Angiology - August 29, 2013 Category: Cardiology Authors: Gao, W., Zhang, Q., Ge, H., Guo, Y., Zhou, Z. Tags: Hemostasis Source Type: research
Comparison of Triple Anti-Platelet Therapy and Dual Anti-Platelet Therapy in Patients With Acute Myocardial Infarction Who Had No-Reflow Phenomenon During Percutaneous Coronary Intervention.
Conclusions: Triple anti-platelet therapy seems to be superior to dual anti-platelet therapy in patients with AMI who had no-reflow phenomenon during PCI. PMID: 23986083 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - August 29, 2013 Category: Cardiology Authors: Lee KH, Ahn Y, Kim SS, Rhew SH, Jeong YW, Jang SY, Cho JY, Jeong HC, Park KH, Yoon NS, Sim DS, Yoon HJ, Kim KH, Hong YJ, Park HW, Kim JH, Cho JG, Park JC, Jeong MH, Cho MC, Kim CJ, Kim YJ, KAMIR (Korea Acute Myocardial Infarction Registry) Investigators Tags: Circ J Source Type: research
Age-Related Decline in Oligodendrogenesis Retards White Matter Repair in Mice [Basic Sciences]
Conclusions— An age-related decline in cyclic AMP response element-binding protein–mediated oligodendrogenesis may compromise endogenous white matter repair mechanisms, and therefore, drugs that activate cyclic AMP response element-binding protein signaling provide a potential therapeutic approach for treating white matter injury in aging brains. (Source: Stroke)
Source: Stroke - August 26, 2013 Category: Neurology Authors: Miyamoto, N., Pham, L.-D. D., Hayakawa, K., Matsuzaki, T., Seo, J. H., Magnain, C., Ayata, C., Kim, K.-W., Boas, D., Lo, E. H., Arai, K. Tags: Animal models of human disease, Other Stroke Treatment - Medical, Other Vascular biology Basic Sciences Source Type: research
RhoA/ROCK-dependent pathway is required for TLR2-mediated IL-23 production in human synovial macrophages: Suppression by cilostazol.
In this study, we investigated whether the RhoA/Rho-kinase pathway is required to elevate TLR2-mediated IL-23 production in synovial macrophages from patients with rheumatoid arthritis (RA), and then examined the suppressive effect of cilostazol on these pathways. IL-23 production was elevated by lipoteichoic acid (LTA), a TLR2 ligand, and this elevation was more prominent in RA macrophages than in those from peripheral blood of normal control. LTA increased the activation of RhoA in association with increased the nuclear translocation of NF-κB and its DNA-binding activity. Pretreatment of RA macrophages with the pharmaco...
Source: Biochemical Pharmacology - August 22, 2013 Category: Drugs & Pharmacology Authors: Park SY, Lee SW, Lee WS, Rhim BY, Lee SJ, Kwon SM, Hong KW, Kim CD Tags: Biochem Pharmacol Source Type: research
Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome
Conclusions: Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome. Both drugs normalize ST-segment elevation and suppress arrhythmogenesis in experimental models of Brugada syndrome. (Source: Heart Rhythm)
Source: Heart Rhythm - August 5, 2013 Category: Cardiology Authors: Tamás Szél, István Koncz, Charles Antzelevitch Tags: Experimental Genetic Source Type: research
Impact of cilostazol on the progression of carotid atherosclerosis in patients with retinal vascular occlusion
In conclusion, cilostazol potently inhibited the progression of carotid IMT and may play a role in the early carotid plaque regression in patients with retinal vascular occlusion. This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - August 1, 2013 Category: Cardiology Authors: Seong‐Man Kim, Kyoung‐Im Cho Tags: Original Research Article Source Type: research
Differential Impact of Cilostazol on Restenosis According to Implanted Stent Type (from a Pooled Analysis of Three DECLARE Randomized Trials)
In conclusion, add-on cilostazol effectively reduced restenosis in patients at high risk for restenosis, particularly in those receiving SES, suggesting the sustainable utility of add-on cilostazol therapy in newer generation drug-eluting stents with comparable efficacy with that of SES. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - July 26, 2013 Category: Cardiology Authors: Seung-Whan Lee, Jung-Min Ahn, Seungbong Han, Gyung-Min Park, Young-Rak Cho, Woo-Seok Lee, Jeong-Yoon Jang, Chang-Hee Kwon, Jong-Young Lee, Won-Jang Kim, Soo-Jin Kang, Young-Hak Kim, Cheol-Whan Lee, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park Tags: Coronary Artery Disease Source Type: research
Thermal Taste and Anti-Aspiration Drugs: a Novel Drug Discovery against Pneumonia.
Abstract Despite the development of strong antibiotics, the pneumonia death is increasing all over the world in these decades. Among the people who died of pneumonia, the majority were 65 years old or over. Although pneumonia is recently categorized into several entities, aspiration pneumonia is included all entities. Therefore, targeting dysphagia and aspiration to treat pneumonia is a promising strategy and anti-aspiration drugs will be a part of pneumonia treatment. The swallowing reflex in elderly people was temperature-sensitive and the improvement of swallowing reflex by temperature stimuli could be mediated ...
Source: Current Pharmaceutical Design - July 26, 2013 Category: Drugs & Pharmacology Authors: Ebihara S, Ebihara T, Gui P, Osaka K, Sumi Y, Kohzuki M Tags: Curr Pharm Des Source Type: research
Cilostazol strengthens the endothelial barrier of postcapillary venules from the rat mesentery in situ.
CONCLUSION: Cilostazol appears to tighten the endothelial barrier in situ, at least in part by inhibiting the cAMP-degrading enzyme in the endothelium. PMID: 23858026 [PubMed - as supplied by publisher] (Source: Phlebology)
Source: Phlebology - July 15, 2013 Category: Internal Medicine Authors: Sugiura Y, Morikawa T, Takenouchi T, Suematsu M, Kajimura M Tags: Phlebology Source Type: research